{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:52:16Z","timestamp":1778125936277,"version":"3.51.4"},"reference-count":10,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,2,10]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Treatment with programmed cell death 1 inhibitors is associated with a wide range of cutaneous immune-related adverse events, with lichenoid eruptions representing one of the major cutaneous toxicities. We describe the case of an 81-year-old man with metastatic melanoma treated with pembrolizumab who subsequently developed a delayed-onset generalized lichenoid dermatitis. After failing multiple lines of systemic immunosuppression, narrowband ultraviolet B (NBUVB) phototherapy three times per week for 17 sessions resulted in a significant clinical response in his cutaneous eruption and was well tolerated. NBUVB is a safe, lower-cost modality that induces local, skin-specific immunosuppression without the toxicities of traditional systemic immunosuppressive agents. To date, this is the first report of use of NBUVB in immune-related lichenoid dermatitis resistant to multiple standard therapies.<\/jats:p>","DOI":"10.1136\/jitc-2020-001831","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T23:10:12Z","timestamp":1616713812000},"page":"e001831","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report"],"prefix":"10.1136","volume":"9","author":[{"given":"Khashayar","family":"Esfahani","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-2931","authenticated-orcid":false,"given":"Meagan-Helen","family":"Henderson Berg","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Zargham","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Billick","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Pehr","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Redpath","sequence":"additional","affiliation":[{"name":"Department of Pathology, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Roshdy","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson H","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"2025100302351635000_9.3.e001831.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100302351635000_9.3.e001831.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062"},{"key":"2025100302351635000_9.3.e001831.3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100302351635000_9.3.e001831.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-005-0565-9"},{"key":"2025100302351635000_9.3.e001831.5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025100302351635000_9.3.e001831.6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to Anti-Programmed cell death 1 and Anti-Programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025100302351635000_9.3.e001831.7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00010"},{"key":"2025100302351635000_9.3.e001831.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2005.00173.x"},{"key":"2025100302351635000_9.3.e001831.9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00405","article-title":"Management of persistent pruritus and lichenoid reaction secondary to nivolumab with Narrowband ultraviolet B phototherapy","volume":"8","author":"Donaldson","year":"2018","journal-title":"Front Oncol"},{"key":"2025100302351635000_9.3.e001831.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.02.002"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:35:23Z","timestamp":1759484123000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,25]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-001831"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001831","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}